FACULTY
Emerging Technologies in Chronic Pain Pharmacotherapies
Including summaries from a symposium held in conjunction with AMCP's 21st Annual Meeting & Showcase in Orlando, Florida
Activity Date: July 2009  — Activity Info: Volume 6, (1)
Goals & Objectives | Faculty | Complete Pre-Test Activity | Introduction | Full Activity Content | CME Test & Evaluation (CME Expired)

 

Full Disclosure Policy Affecting CE Activities:
As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of the University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with a commercial interest. The Course Director and Participating Faculty reported the following:

COURSE DIRECTOR

Bruce R. Canaday, PharmD, FASHP, FAPhA
Director, Department of Pharmacotherapy
South East Area Health Education Center
Wilmington, North Carolina
Vice-Chair, Division of Pharmacy Practice and Experiential Education
University of North Carolina
Chapel Hill, North Carolina
• Dr Canaday reports having no significant financial or advisory relationships with corporate organizations related to this activity.


PARTICIPATING FACULTY

John P. Barbuto, MD, PC
Medical Director
Neurology-in-Focus
HealthSouth Rehabilitation Hospital
Editorial Advisory Board — Journal of Managed Care Pharmacy
Sandy, Utah
• Dr Barbuto reports having no significant financial or advisory relationships with corporate organizations related to this activity.

Lynn Webster, MD, FACPM, FASAM
Medical Director
Lifetree Clinical Research and Pain Clinic
Salt Lake City, Utah
• Dr Webster reports receiving grants/research support from Abbott Laboratories, Advanced Bionics, LLC, Alpharma Pharmaceuticals (acquired by King Pharmaceuticals, Inc), Ameritox, Arrya Hi-Tech Energy, AstraZeneca, Boehringer Ingelheim, Cervélo, CoMentis, Inc, Durect Corporation, Elan Corporation, plc, Elite, Forest Laboratories, Inc, GlaxoSmithKline, Jazz, King Pharmaceuticals, Inc, Medtronic, Merck & Co, Inc, Nektar, NeurogesX, Pain Therapeutics, Inc, Purdue Pharma LP, QRxPharma Ltd, Respironics, Inc, Takeda Pharmaceutical Company Limited, TorreyPines Therapeutics, Wyeth, and Zars Pharma, Inc; receiving advisory board honoraria from Alpharma Pharmaceuticals (acquired by King Pharmaceuticals, Inc), Ameritox, King Pharmaceuticals, Inc, Nektar, Nervo, Neuromed, Purdue Pharma LP, and QRxPharma Ltd; and serving as a consultant for Ameritox, Boston Scientific, Cephalon, Inc, Corona Productions, Elan Corporation, plc, King Pharmaceuticals, Inc, MediCom Worldwide, Inc, Medscape, and Medtronic.

Notice: In accordance with ACPE Criteria for Quality, the audience is advised that all faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs or devices.

University of Tennessee Advanced Studies in Pharmacy provides disclosure information from contributing authors, lead presenters, and participating faculty. University of Tennessee Advanced Studies in Pharmacy does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.

     
Home | Contact Us | View Account | Need Help?